166.21 USD
+0.55 (+0.33%)
166.21 USD
0 (0%)
Taking everything into account, RGEN scores 5 out of 10 in our fundamental rating. RGEN was compared to 57 industry peers in the Life Sciences Tools & Services industry. While RGEN has a great health rating, its profitability is only average at the moment. RGEN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RGEN was profitable.
In the past year RGEN had a positive cash flow from operations.
Of the past 5 years RGEN 4 years were profitable.
In the past 5 years RGEN always reported a positive cash flow from operatings.
1.2 Ratios
RGEN has a Return On Assets of 0.06%. This is in the better half of the industry: RGEN outperforms 68.42% of its industry peers.
RGEN has a Return On Equity of 0.08%. This is in the better half of the industry: RGEN outperforms 70.18% of its industry peers.
With a Return On Invested Capital value of 1.05%, RGEN perfoms like the industry average, outperforming 59.65% of the companies in the same industry.
RGEN had an Average Return On Invested Capital over the past 3 years of 2.65%. This is significantly below the industry average of 13.99%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROIC | 1.05% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
The Profit Margin of RGEN (0.25%) is better than 68.42% of its industry peers.
RGEN has a better Operating Margin (6.58%) than 63.16% of its industry peers.
In the last couple of years the Operating Margin of RGEN has declined.
RGEN has a Gross Margin (51.59%) which is in line with its industry peers.
In the last couple of years the Gross Margin of RGEN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RGEN is destroying value.
Compared to 1 year ago, RGEN has more shares outstanding
RGEN has more shares outstanding than it did 5 years ago.
RGEN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 7.58 indicates that RGEN is not in any danger for bankruptcy at the moment.
The Altman-Z score of RGEN (7.58) is better than 85.96% of its industry peers.
The Debt to FCF ratio of RGEN is 5.05, which is a neutral value as it means it would take RGEN, 5.05 years of fcf income to pay off all of its debts.
RGEN has a better Debt to FCF ratio (5.05) than 68.42% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that RGEN is not too dependend on debt financing.
RGEN has a Debt to Equity ratio (0.26) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Altman-Z | 7.58 |
ROIC/WACC0.1
WACC10.51%
2.3 Liquidity
RGEN has a Current Ratio of 8.36. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RGEN (8.36) is better than 91.23% of its industry peers.
A Quick Ratio of 7.14 indicates that RGEN has no problem at all paying its short term obligations.
RGEN's Quick ratio of 7.14 is amongst the best of the industry. RGEN outperforms 89.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 |
3. Growth
3.1 Past
RGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.17%, which is quite impressive.
The Earnings Per Share has been growing slightly by 7.11% on average over the past years.
Looking at the last year, RGEN shows a decrease in Revenue. The Revenue has decreased by -8.54% in the last year.
The Revenue has been growing by 18.62% on average over the past years. This is quite good.
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
3.2 Future
RGEN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.53% yearly.
RGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.90% yearly.
EPS Next Y14.84%
EPS Next 2Y19.3%
EPS Next 3Y22.48%
EPS Next 5Y25.53%
Revenue Next Year15.58%
Revenue Next 2Y14%
Revenue Next 3Y14.31%
Revenue Next 5Y15.9%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 100.13, RGEN can be considered very expensive at the moment.
The rest of the industry has a similar Price/Earnings ratio as RGEN.
Compared to an average S&P500 Price/Earnings ratio of 26.92, RGEN is valued quite expensively.
A Price/Forward Earnings ratio of 78.91 indicates a quite expensive valuation of RGEN.
The rest of the industry has a similar Price/Forward Earnings ratio as RGEN.
RGEN is valuated expensively when we compare the Price/Forward Earnings ratio to 23.46, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 100.13 | ||
| Fwd PE | 78.91 |
4.2 Price Multiples
RGEN's Enterprise Value to EBITDA is on the same level as the industry average.
RGEN's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 87.87 | ||
| EV/EBITDA | 82.41 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RGEN does not grow enough to justify the current Price/Earnings ratio.
RGEN's earnings are expected to grow with 22.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)6.75
PEG (5Y)14.09
EPS Next 2Y19.3%
EPS Next 3Y22.48%
5. Dividend
5.1 Amount
No dividends for RGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
166.21
+0.55 (+0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners110.01%
Inst Owner Change16.45%
Ins Owners0.45%
Ins Owner Change-2.87%
Market Cap9.36B
Revenue(TTM)707.89M
Net Income(TTM)1.74M
Analysts81.43
Price Target193.06 (16.15%)
Short Float %8.21%
Short Ratio4.76
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.48%
Min EPS beat(2)-6.83%
Max EPS beat(2)7.78%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-6.83%
Max EPS beat(4)10.73%
EPS beat(8)4
Avg EPS beat(8)4.05%
EPS beat(12)8
Avg EPS beat(12)8.34%
EPS beat(16)12
Avg EPS beat(16)11.45%
Revenue beat(2)2
Avg Revenue beat(2)2.11%
Min Revenue beat(2)2.07%
Max Revenue beat(2)2.15%
Revenue beat(4)3
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)2.15%
Revenue beat(8)3
Avg Revenue beat(8)-0.3%
Revenue beat(12)3
Avg Revenue beat(12)-1%
Revenue beat(16)7
Avg Revenue beat(16)0.58%
PT rev (1m)0.98%
PT rev (3m)5.47%
EPS NQ rev (1m)-0.24%
EPS NQ rev (3m)-12.15%
EPS NY rev (1m)-0.18%
EPS NY rev (3m)-0.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.04%
Revenue NY rev (1m)0.29%
Revenue NY rev (3m)0.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 100.13 | ||
| Fwd PE | 78.91 | ||
| P/S | 13.22 | ||
| P/FCF | 87.87 | ||
| P/OCF | 71.48 | ||
| P/B | 4.49 | ||
| P/tB | 16.27 | ||
| EV/EBITDA | 82.41 |
EPS(TTM)1.66
EY1%
EPS(NY)2.11
Fwd EY1.27%
FCF(TTM)1.89
FCFY1.14%
OCF(TTM)2.33
OCFY1.4%
SpS12.58
BVpS37.01
TBVpS10.21
PEG (NY)6.75
PEG (5Y)14.09
Graham Number37.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROCE | 1.67% | ||
| ROIC | 1.05% | ||
| ROICexc | 1.43% | ||
| ROICexgc | 5.46% | ||
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% | ||
| FCFM | 15.04% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexgc growth 3Y-71.22%
ROICexgc growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score6
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Debt/EBITDA | 4.85 | ||
| Cap/Depr | 37.9% | ||
| Cap/Sales | 3.45% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 117.95% | ||
| Profit Quality | 6126.58% | ||
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 | ||
| Altman-Z | 7.58 |
F-Score6
WACC10.51%
ROIC/WACC0.1
Cap/Depr(3y)91.1%
Cap/Depr(5y)111.21%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
EPS Next Y14.84%
EPS Next 2Y19.3%
EPS Next 3Y22.48%
EPS Next 5Y25.53%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
Revenue Next Year15.58%
Revenue Next 2Y14%
Revenue Next 3Y14.31%
Revenue Next 5Y15.9%
EBIT growth 1Y163.23%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year69.07%
EBIT Next 3Y37.03%
EBIT Next 5Y36%
FCF growth 1Y9.1%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-10.84%
OCF growth 3Y13.8%
OCF growth 5Y21.15%
REPLIGEN CORP / RGEN FAQ
Can you provide the ChartMill fundamental rating for REPLIGEN CORP?
ChartMill assigns a fundamental rating of 5 / 10 to RGEN.
What is the valuation status of REPLIGEN CORP (RGEN) stock?
ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.
What is the profitability of RGEN stock?
REPLIGEN CORP (RGEN) has a profitability rating of 4 / 10.
What is the valuation of REPLIGEN CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for REPLIGEN CORP (RGEN) is 100.13 and the Price/Book (PB) ratio is 4.49.
Can you provide the expected EPS growth for RGEN stock?
The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 14.84% in the next year.